2012-11-13T18:40:41-06:00 2011-12-31 346565596 ERNST & YOUNG US LLP 18111 VON KARMAN AVENUE SUITE 1000 IRVINE CA 92612 990 2011-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 THOMAS D GORDON 3102488327 2012-11-13 1 KARA ADAMS P00023315 9497942300 2011 2016-02-24 21:20:13Z ERIC N MARTON 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 1329412 0 X WWW.CALIFORNIAHEARTCENTER.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 18 13 0 19 0 0 2355777 1280861 27000 29520 12029 19031 2310 0 2397116 1329412 0 0 0 0 1243501 1113280 0 0 0 673594 458228 1917095 1571508 480021 -242096 1223690 966262 77487 81870 1146203 884392 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1103728 29520 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2011: CONSENSUS CONFERENCE: CRUCIAL CONVERSATIONS IN THORACIC TRANSPLANT NURSING: SPONSORED JOINTLY BY THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION AND THE CEDARS-SINAI HEART INSTITUTE IN COOPERATION WITH THE ISHLT SCIENTIFIC COUNCIL FOR NURSING, HEALTH SCIENCE AND ALLIED HEALTH, "CRUCIAL CONVERSATIONS IN THORACIC TRANSPLANT NURSING" WAS HELD ON APRIL 12TH, 2011 IN SAN DIEGO, CALIFORNIA. THE MEETING WAS DESIGNED TO PROVIDE A FORUM FOR TRANSPLANT NURSES AND OTHER ALLIED HEALTH PROFESSIONALS TO DISCUSS THE EVOLUTION OF NURSING IN THIS SPECIALIZED AREA OF MEDICINE AND THE FUTURE ROLE OF TRANSPLANT NURSE PROFESSIONALS IN CREATING STANDARDS FOR PATIENT CARE AND EDUCATION. THE CONFERENCE WAS ATTENDED BY 71 TRANSPLANT NURSE PROFESSIONALS FROM 14 COUNTRIES. WITH JON KOBASHIGAWA SERVING AS A CONFERENCE ADVISOR AND CHAIR OF THE PLANNING COMMITTEE, THE CONFERENCE WAS EXTREMELY WELL RECEIVED. A REPORT ON THE CONSENSUS CONFERENCE IS EXPECTED TO BE PUBLISHED LATER THIS YEAR, WITH THE HOPE OF BEING A FIRST STEP IN ESTABLISHING TRANSPLANT NURSING CRITERIA AND COMPETENCIES.OPTIMAL CARE AND NEW THERAPIES FOR ADVANCED HEART DISEASE: DESIGNED AS AN EDUCATIONAL SERIES FOR COMMUNITY PHYSICIANS, COURSES WERE OFFERED ON MAY 21, 2011 IN BAKERSFIELD, CALIFORNIA ON SEPTEMBER 17TH, 2011 IN NEWPORT BEACH, CALIFORNIA AND ON OCTOBER 22ND, 2011 IN LAS VEGAS, NEVADA. THESE ONE-DAY COURSES FEATURED EXPERT PRESENTERS ON TOPICS RELATED TO THE DIAGNOSIS, TREATMENT AND MANAGEMENT OF ADVANCED HEART DISEASE, FOCUSING ON CORE COMPETENCIES OF ADVANCED HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT, SURGICAL INTERVENTIONS AND TRANSPLANT CARDIOLOGY. ATTENDED BY COMMUNITY CARDIOLOGISTS, INTERNISTS, FAMILY PRACTICE PHYSICIANS AND ALLIED HEALTH STAFF, THE COURSE INCLUDED A COMBINATION OF DIDACTIC LECTURES AND CASE BASED PRESENTATIONS WITH EMPHASIS ON GUIDELINES, KNOWLEDGE, AND PRACTICE MANAGEMENT.SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS WERE OFFERED TO EIGHT STUDENTS IN MAY 2011. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED AND ACCEPTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES A FIRST YEAR MEDICAL STUDENT FROM THE UNIVERSITY OF NEVADA LAS VEGAS, AND UNDERGRADUATE STUDENTS FROM AMHERST COLLEGE, BROWN UNIVERSITY, WASHINGTON UNIVERSITY, AND THE UNIVERSITY OF CALIFORNIA LOS ANGELES.HEART TRANSPLANT JOURNAL CLUB: IN 2011, THE FOUNDATION BEGAN COORDINATING AND SPONSORING MONTHLY MEETINGS FOR PHYSICIANS, FELLOWS, RESIDENTS AND STUDENTS TO REVIEW AND DISCUSS JOURNAL ARTICLES RELATED TO TRANSPLANTATION. HELD ON THE FIRST TUESDAY OF EACH MONTH, JOURNAL CLUBS ARE MODERATED BY DR. JIGNESH PATEL.PATIENT EDUCATION SERIES: PATIENT LECTURES BY DR. JON KOBASHIGAWA WERE ORGANIZED IN MAY AND DECEMBER 2011. COVERING "CURRENT TRENDS IN HEART TRANSPLANTATION", THE PROGRAM PROVIDED BOTH PRE AND POST-TRANSPLANT PATIENTS WITH AN OVERVIEW OF ADVANCES IN THE FIELD OF HEART TRANSPLANTATION AND INCLUDED AN EXTENSIVE QUESTION AND ANSWER SESSION. RESEARCH STUDIES (ONGOING AND NEWLY INITIATED):STUDY TITLE: EARLY INVASIVE MONITORING ATTENUATION THROUGH GENE EXPRESSION (EIMAGE)SPONSOR: EXPRESSION DIAGNOSTICS INC.PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF GENE EXPRESSION BLOOD TESTS TO THE COMMONLY USED METHOD OF HEART BIOPSIES FOR MONITORING ACUTE REJECTION IN PATIENTS WHO HAVE HAD A HEART TRANSPLANT. REJECTION IS PART OF THE BODY'S NATURAL DEFENSE AGAINST DISEASE AND IT IS A NORMAL RESPONSE BY THE BODY'S IMMUNE SYSTEM TO A TRANSPLANTED ORGAN. HISTORICALLY, THE STANDARD METHOD TO DETERMINE REJECTION HAS BEEN THROUGH ROUTINE HEART BIOPSIES. HOWEVER, A HEART BIOPSY IS AN INVASIVE PROCEDURE THAT REQUIRES PUTTING A SMALL TUBE THROUGH THE NECK OR GROIN INTO THE HEART; A VERY SMALL PIECE OF THE HEART TISSUE IS REMOVED AND EXAMINED FOR SIGNS OF REJECTION. BECAUSE OF THIS, THERE IS A GREAT DEAL OF INTEREST IN USING NON-INVASIVE METHODS TO DIAGNOSE REJECTION IN HEART TRANSPLANT PATIENTS. THE STUDY AIMS TO DEMONSTRATE THAT ACUTE REJECTION OF THE TRANSPLANTED HEART CAN BE SAFELY MONITORED USING THIS BLOOD TEST, FIRST COMMERCIALLY INTRODUCED IN 2005, SO THAT REPEATED HEART BIOPSIES CAN BE AVOIDED. THIS BLOOD TEST, CALLED GENE EXPRESSION PROFILING (GEP), BRAND NAMED ALLOMAP, IDENTIFIES THE EXPRESSION OF GENES ON WHITE BLOOD CELLS THAT CIRCULATE IN THE BLOOD AND CAUSE THE HEART TO BE REJECTED.STUDY TITLE: CLINICAL TRIALS IN ORGAN TRANSPLANTATION (CTOT-11): NOVEL THERAPIES TO IMPROVE RENAL AND CARDIAC ALLOGRAFT OUTCOMESSPONSOR: NIHPROJECT SUMMARY: TRANSPLANTATION IS THE IDEAL THERAPY FOR END STAGE HEART AND END STAGE KIDNEY FAILURE, BUT ALLOGRAFT SURVIVAL AND FUNCTION REMAIN SUBOPTIMAL. THIS CTOT RENEWAL APPLICATION WILL BUILD UPON THE FINDINGS RESULTING FROM THE PREVIOUS 4 YEARS OF STUDYING BIOMARKERS AND MECHANISMS OF INJURY IN HEART AND KIDNEY TRANSPLANT RECIPIENTS IN AN EFFORT TO DEVELOP THERAPIES TAILORED TO INDIVIDUAL PATIENTS. THE OVERRIDING CLINICAL HYPOTHESIS IS THAT SPECIFICALLY DESIGNED THERAPIES GUIDED BY RATIONALLY CHOSEN NONINVASIVE IMMUNE MONITORING WILL IMPROVE OUTCOMES IN HEART AND KIDNEY TRANSPLANT RECIPIENTS. THE STUDY WILL INVOLVE IDENTIFYING HEART TRANSPLANT CANDIDATES AT HIGH RISK FOR ANTIBODY MEDIATED INJURY (HIGH PRA) AND PERFORMING A PILOT STUDY TO DETERMINE THE SAFETY AND EFFICACY OF DESENSITIZATION USING A COMBINATION OF B CELL DEPLETION (RITUXIMAB), IVIG PLASMAPHERESIS. THE STUDY WILL TEST THE HYPOTHESIS THAT DESENSITIZATION WILL LOWER PRA, DIMINISH THE WAITING TIME TO HEART TRANSPLANTATION AND RESULT IN ACCEPTABLE 1 YEAR GRAFT SURVIVAL AND FUNCTION. PATIENTS WILL BE ENROLLED FROM WITHIN A POWERFUL CONSORTIUM OF 22 NORTH AMERICAN HEART TRANSPLANT CENTERS THAT WAS DEVELOPED FOR THE ONGOING HEART TRANSPLANTATION CTOT05 STUDY. ASSOCIATED MECHANISTIC STUDIES WILL DETERMINE HOW THE DESENSITIZATION PROTOCOL IMPACTS PREFORMED ALLOREACTIVE T AND B CELL IMMUNITY AND WILL TEST THE HYPOTHESIS THAT RESIDUAL B AND T CELL IMMUNE MEMORY WITH REACTIVITY TO DONOR ANTIGENS MEDIATES POST-TRANSPLANT ALLOGRAFT INJURY.STUDY TITLE: RISK FACTORS AND OUTCOMES POST HEART TRANSPLANTATIONSPONSOR: INTERNALPROJECT SUMMARY: THE PURPOSE OF THIS CLINICAL RESEARCH IS TO RETROSPECTIVELY REVIEW DATA ON PATIENTS TRANSPLANTED AT CEDARS-SINAI MEDICAL CENTER TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM SURVIVAL POST HEART TRANSPLANTATION. THE DATA THAT WILL BE COLLECTED AND ANALYZED WILL BE EXTRACTED FROM MEDICAL RECORDS, AND THIS DATA WILL CONSIST OF DEMOGRAPHICS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS. DEMOGRAPHICS WILL CONSIST OF BOTH RECIPIENT AND DONOR CHARACTERISTICS. OUTCOMES MAY CONSIST OF LABORATORY RESULTS, PROCEDURAL RESULTS, CLINICAL DIAGNOSES, HOSPITALIZATION INFORMATION, LIST OF MEDICATIONS, HOSPITALIZATIONS, LABORATORY RESULTS, AS WELL AS ANY OTHER ADDITIONAL RELEVANT DATA. WITH SUCH AN EXTENSIVE HEART TRANSPLANT PROGRAM WITH A LARGE COHORT OF PATIENTS, DATA FROM OUR RESEARCH WOULD GREATLY ENHANCE AND BENEFIT THE FIELD OF HEART TRANSPLANTATION. BY EVALUATING THE DATA OF ALL HEART TRANSPLANT PATIENTS IN ONE COMPREHENSIVE DATABASE STUDY, WE MAY BE ABLE TO IMPROVE OUR UNDERSTANDING OF HEART TRANSPLANTATION AS WELL AS THE QUALITY OF LIFE OF HEART TRANSPLANT PATIENTS. 1103728 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 5 0 1 0 0 0 0 0 0 0 0 0 0 0 X 18 13 1 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X ERIC MARTON 3102488327 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 X JON KOBASHIGAWA MD 2.00 X X 500 0 0 KEENAN BEHRLE 2.00 X X 0 0 0 JAMES HAMILTON 2.00 X X 0 0 0 KAY DILLARD 2.00 X 0 0 0 THOMAS D GORDON 1.00 X X 0 892737 215598 RUSSELL FAUCETT 2.00 X 0 0 0 IRENE FURLONG 2.00 X 0 0 0 MICHELE HAMILTON MD 2.00 X 500 0 0 RICHARD B JACOBS 1.00 X 0 892185 238563 E ERIC JOHNSON 2.00 X 0 0 0 JOSEPH O LAMPE 2.00 X 0 0 0 EDUARDO MARBAN MD 1.00 X 0 2003956 206666 LAURENCE MARTON MD 2.00 X 0 0 0 ARTHUR J OCHOA 1.00 X 0 1065179 56841 WILLIAM OUCHI PHD 2.00 X 0 0 0 EDWARD PRUNCHUNAS 1.00 X 0 1181611 263882 LAWRENCE SOUZA PHD 2.00 X 0 0 0 PHILLIP L WILLIAMS 2.00 X 0 0 0 ERIC N MARTON 30.00 X 0 328263 42153 CHRISTINE SUMBI 40.00 X 0 128032 15201 1000 6491963 1038904 0 0 1 0 0 1277550 3311 1280861 EDUCATIONAL PROGRAMS 611430 29520 29520 29520 18834 18834 197 197 197 197 1329412 29520 0 19031 285343 285343 701535 701535 35471 35471 17981 17981 72950 72950 2400 2400 3015 3015 58904 33575 25329 1250 1250 18575 18192 383 7594 3797 3797 166438 166438 399 399 107902 107902 43421 43421 7098 2625 4473 BANK/CREDIT CARD FEES 4607 4607 STORAGE 4198 4198 DUES & SUBSCRIPTIONS 3616 3146 470 LICENSES & TAXES 1656 1656 27155 27155 1571508 1103728 467780 0 71431 66614 137417 14678 7098 4687 461008 151030 353400 309978 641233 559744 2550 0 10561 10561 1223690 966262 77487 81870 77487 81870 X 1146203 884392 1146203 884392 1223690 966262 X -242096 -19715 X 0 0 0 X 393819 1380752 1202798 2355777 1280861 6614007 393819 1380752 1202798 2355777 1280861 6614007 2980277 3633730 28302 11200 7427 12029 18834 77792 21443 25 21468 6713267 244958 0.54130 0.41390 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 346762 80920 265842 77162 51567 25595 37084 18543 18541 309978 0 1 0 0 0 0 0 0 0 THOMAS D GORDON 0 464624 0 224848 0 203265 0 186386 0 29212 0 1108335 0 0 RICHARD B JACOBS 0 502258 0 239025 0 150902 0 221819 0 16744 0 1130748 0 0 EDUARDO MARBAN MD 0 1166497 0 238469 0 598990 0 164765 0 41901 0 2210622 0 0 ARTHUR J OCHOA 0 400624 0 592686 0 71869 0 20945 0 35896 0 1122020 0 0 EDWARD PRUNCHUNAS 0 602262 0 282153 0 297196 0 224042 0 39840 0 1445493 0 0 ERIC N MARTON 0 273831 0 35500 0 18932 0 14765 0 27388 0 370416 0 0 PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. ONE INDIVIDUAL ALSO RECEIVED PAYOUT FROM AMOUNTS ACCRUED IN A PRIOR YEAR. THE FOLLOWING OFFICERS, DIRECTORS, KEY EMPLOYEES AND HIGHEST-COMPENSATED EMPLOYEES RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2011. THOMAS D. GORDON 177,961 RICHARD B. JACOBS 133,742 EDUARDO MARBAN, MD 509,443 ERIC N. MARTON 17,080 ARTHUR J. OCHOA 68,048 EDWARD PRUNCHUNAS 239,222 SUPPLEMENTAL INFORMATION PART III SCHEDULE J, PART I, LINE 3: THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, LINE 15. PROGRAM SERVICE STATEMENT STUDY TITLE: HEARTSBREATH TEST FOR HEART TRANSPLANT REJECTION SPONSOR: MENSANNA RESEARCH PROJECT SUMMARY: THIS RESEARCH WILL EVALUATE WHETHER THE HEARTSBREATH DEVICE CAN ASSIST IN DIAGNOSING HEART TRANSPLANT REJECTION IN PATIENTS WHO'VE RECEIVED A HEART TRANSPLANT DURING THE PRECEDING 12 MONTHS AND ARE ABOUT TO RECEIVE AN ENDOMYOCARDIAL BIOPSY. THE MAIN AIM OF THIS STUDY IS TO VALIDATE THE ACCURACY OF THE DEVICE TO DETECT HEART TRANSPLANT REJECTION, BY COLLECTING SAMPLES PRIOR TO BIOPSY AND COMPARING THEM WITH THE BIOPSY RESULTS. PATIENTS WHO HAVE RECEIVED A HEART TRANSPLANT WITHIN THE PREVIOUS 12 MONTHS AND ARE SCHEDULED FOR A ROUTINE ENDOMYOCARDIAL BIOPSY MAY BE ELIGIBLE FOR PARTICIPATION IN THIS TRIAL. RIGHT VENTRICULAR ENDOMYOCARDIAL BIOPSY IS CURRENTLY THE "GOLD STANDARD" FOR DIAGNOSIS OF HEART TRANSPLANT REJECTION. ALTHOUGH CONSIDERED SAFE, THE PROCEDURE IS INVASIVE AND MAY CAUSE COMPLICATIONS. ALSO, THERE ARE DISCREPANCIES BETWEEN BIOPSY READINGS WITH REGARD TO GRADING OF REJECTIONS SUFFICIENT TO HAVE ADVERSE TREATMENT IMPLICATIONS. SEVERAL NON-INVASIVE TESTS FOR HEART TRANSPLANT REJECTION HAVE BEEN PROPOSED, HOWEVER, THEIR ACCURACY IS GENERALLY TOO POOR TO GUIDE CLINICAL DECISION MAKING IN INDIVIDUAL PATIENTS. THE BREATH TESTS USES BIOMARKERS FOUND IN HUMAN BREATH AS INDICATORS FOR REJECTION AND ITS INTENSITY. A SCREENING BREATH TEST COULD POTENTIALLY IDENTIFY TRANSPLANT RECIPIENTS AT LOW RISK OF GRADE 3 REJECTION AND REDUCE THE NUMBER OF ENDOMYOCARDIAL BIOPSIES. STUDY TITLE: ACE INHIBITION AND CARDIAC ALLOGRAFT VASCULOPATHY SPONSOR: NIH/STANFORD UNIVERSITY PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO INVESTIGATE THE EFFECT OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE I), RAMIPRIL, AN ANTIHYPERTENSIVE AGENT, ON THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IS A LEADING CAUSE OF MORBIDITY AND MORTALITY AFTER HEART TRANSPLANT. DESPITE ADVANCES IN PROPHYLAXIS AGAINST REJECTION AND INFECTION, AS WELL AS IMPROVED CONTROL OF TRADITIONAL ATHEROSCLEROTIC RISK FACTORS, SIGNIFICANT DEVELOPMENT OF ATHEROSCLEROTIC PLAQUE AND DETRIMENTAL VASCULAR REMODELING OCCUR EARLY AFTER ORTHOTOPIC HEART TRANSPLANTATION (OHT). THE INVESTIGATORS HOPE TO DETERMINE WHETHER ACE I THERAPY WITH RAMIPRIL EARLY AFTER OHT IMPACTS THE DEVELOPMENT OF CAV, AND LEARN IF THE USE OF ACE I INCREASES THE NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPC) RESULTING IN IMPROVED ENDOTHELIAL FUNCTION AND LESS ATHEROSCLEROSIS. THE PRIMARY OBJECTIVE IS TO INVESTIGATE THE EFFECT OF ACE I ON THE DEVELOPMENT OF CAV IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. STUDY TITLE: EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY SPONSOR: INTERNAL PROJECT SUMMARY: CARDIAC TRANSPLANTATION IS CURRENTLY THE PROCEDURE OF CHOICE FOR SELECTED PATIENTS WITH END-STAGE HEART DISEASE THAT IS NOT AMENABLE TO FURTHER MEDICAL INTERVENTION OR CONVENTIONAL CARDIAC PROCEDURES. WITH THE ADVENT OF MORE EFFECTIVE IMMUNOSUPPRESSIVE AGENTS, THE DEFINITION OF THE SUCCESSFULLY MANAGED HEART TRANSPLANT RECIPIENT IS EVOLVING BEYOND THE IMMEDIATE CHALLENGE OF PREVENTING ACUTE REJECTION. THE PURPOSE OF THIS SURVEY STUDY IS TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM OUTCOMES AND QUALITY OF LIFE POST HEART TRANSPLANTATION. A SURVEY INSTRUMENT TO OBTAIN POST HEART TRANSPLANT OUTCOMES DATA ON ABOUT 1,000 PATIENTS WILL BE EMPLOYED. DATA TO BE COLLECTED WILL INCLUDE DEMOGRAPHIC DATA, PSYCHOSOCIAL DATA AND PHYSICAL DATA. STUDY TITLE: PROSPECTIVE, MULTI-CENTER, RANDOMIZED CLINICAL INVESTIGATION OF TRANSMEDICS ORGAN CARE SYSTEM (OCS) FOR CARDIAC USE SPONSOR: TRANSMEDICS, INC. PROJECT SUMMARY: THE TRANSMEDICS ORGAN CARE SYSTEM IS A PORTABLE ORGAN PERFUSION AND MONITORING SYSTEM INTENDED TO PRESERVE A DONATED HEART IN A BEATING STATE DURING TRANSPORT FOR THE EVENTUAL TRANSPLANTATION INTO A RECIPIENT. THE ORGAN CARE SYSTEM (OCS) MAINTAINS ORGAN VIABILITY BY PROVIDING A CONTROLLED ENVIRONMENT, CONTINUOUSLY PERFUSING THE DONATED HEART WITH WARM, OXYGENATED BLOOD, SUPPLEMENTED WITH THE TRANSMEDICS CARDIAC SOLUTION SET. THE BLOOD IS COLLECTED FROM THE DONOR AND IS CONTINUOUSLY CIRCULATED TO THE ORGAN IN A CLOSED CIRCUIT ALONG WITH THE CARDIAC SOLUTION SET. THE OCS PRESERVES THE HEART AND MONITORS THE ORGAN'S PERFUSION PARAMETERS IMMEDIATELY AFTER EXPLANTATION FROM A DONOR AND CONNECTION TO THE DEVICE, DURING TRANSPORTATION TO THE RECIPIENT SITE, AND UNTIL DISCONNECTION FROM THE DEVICE. THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF THE OCS WITH THE EXISTING COLD STATIC CARDIOPLEGIA STANDARD OF CARE FOR THE PRESERVATION OF DONOR HEARTS. STUDY TITLE: A POSTMARKETING OBSERVATIONAL STUDY TO ASSESS RESPIRATORY TRACT ADVERSE EVENTS IN PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH TYVASO(R) (TREPROSTINIL) INHALATION SOLUTION SPONSOR: UNITED THERAPEUTICS PROJECT SUMMARY: TYVASO(R) (TREPROSTINIL) IS AN INHALED PROSTACYCLIN VASODILATOR RECENTLY APPROVED IN THE US FOR GROUP 1 PULMONARY ARTERIAL HYPERTENSION PATIENTS. DURING THE APPROVAL PROCESS, THE FDA EXPRESSED CONCERNS THAT TREPROSTINIL MAY BE IRRITATING TO THE RESPIRATORY TRACT WHEN ADMINISTERED BY THE INHALATION ROUTE. THUS, A POST MARKETING REQUIREMENT HAS BEEN MANDATED, SPECIFICALLY A LONG-TERM OBSERVATIONAL STUDY TO FURTHER EVALUATE THE POTENTIAL ASSOCIATION BETWEEN TREPROSTINIL AND ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS. THIS STUDY WILL BE A LONG-TERM OBSERVATIONAL STUDY IN THE US THAT WILL INCLUDE 1000 PATIENT-YEARS OF MONITORING IN TYVASO-TREATED PATIENTS, AND 1000 PATIENT-YEARS OF FOLLOW-UP IN MATCHED CONTROLS RECEIVING OTHER FDA APPROVED TREATMENTS FOR PULMONARY HYPERTENSION. THE PRIMARY OBJECTIVE OF THE STUDY IS TO DESCRIBE THE TYPE AND INCIDENCE OF ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH CURRENT OR RECENT TREATMENT WITH TYVASO FOR PAH. THE SECONDARY OBJECTIVE OF THE STUDY IS TO COMPARE THE INCIDENCE OF SELECTED ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS IN PATIENTS TREATED WITH TYVASO FOR PAH WITH PATIENTS NOT TREATED WITH TYVASO FOR PAH. FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/11 AND 6/30/12 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/11. FORM 990, PART VI, SECTION A, LINE 2 LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, PRESIDENT HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION FORM 990, PART VI, SECTION B, LINE 11 THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. FORM 990 PART VII - AVERAGE HOURS PER WEEK DEVOTED TO RELATED ORGANIZATIONS THOMAS D. GORDON 65 HOURS RICHARD B. JACOBS 61 HOURS EDUARDO MARBAN, MD 60 HOURS ARTHUR J. OCHOA 65 HOURS EDWARD PRUNCHUNAS 65 HOURS ERIC N. MARTON 30 HOURS CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -19,715. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 HEALTHCARE CA 501(C)(3) LINE 3 N/A 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 200 N ROBERTSON BOULEVARD 101 BEVERLY HILLS CA 90211 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 11A, I CEDARS-SINAI MEDICAL CENTER 1 1 GREATER VALLEY MANAGEMENT SERVICES ORGANIZATION INC 6500 WILSHIRE BLVD 8TH FLOOR LOS ANGELES CA 90048 954439758 MANAGEMENT FUNCTIONS CA N/A C OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLOOR LOS ANGELES CA 90048 954522779 INFORMATION SYSTEMS CA N/A C 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0